Anokion SA, a Swiss biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, today announced the acquisition of Kanyos Bio, Inc. and the completion of a $40 million Series B financing.
Anokion has come a long way, according to John A. Hohneker, MD, president and chief executive officer of Anokion, who said, “Since our founding, Anokion has developed and consolidated significant insights and applications for treating both prevalent and rare autoimmune diseases, with an initial focus on people affected by celiac disease and multiple sclerosis.”
The Kanyos acquisition adds KAN-101 to the portfolio, an antigen-specific treatment for celiac disease currently in late preclinical development, with an investigational new drug (IND) application expected to be filed with the FDA by the end of 2019. Originally founded in collaboration with Anokion in 2015, Kanyos leveraged the Anokion platform to rapidly progress KAN-101 into IND-enabling studies. Together with Anokion’s lead product ANK-780, an antigen-specific treatment for multiple sclerosis, the Company anticipates having two programs in clinical development within the next 12 months.
The company also strengthened their leadership team since Laura Brass, PhD, a managing director at Novartis Venture Fund, also joined Anokion’s board of directors. In addition, Anokion further strengthened its management team with the appointment of Raj Manchanda, PhD, as chief technical operations officer and the promotion of Deborah Geraghty, PhD, to chief operating officer.
TrialSite News is excited to see how these transformative transactions and management changes position the company for the next stage of growth as multiple programs advance toward clinical development.
Call to Action: Want to stay updated on Anokion’s new advancements? Visit their website, and to get in touch with the trial investigators, we invite you to use TrialSite News’ Matching Network.